ENCHANT-1 creating right syntax for Synta Pharmaceuticals Corp (NASDAQ:SNTA)

Posted by Ryan Mandell July 30, 2013 0 Comment 781 views


Synta Pharmaceuticals Corp (NASDAQ:SNTA) shares rose 41.31% in Monday’s close after the company announced results of a mid-stage study of ganatespib, its drug for breast cancer treatment. SNTA said that the results supported its expansion.

As per the trial-design, it would be able to transition to the second-stage of enrollment if a minimum of one patient was able to achieve objective tumor-response. This is a measure of tumor-size reduction.

The study is codenamed ENCHANT-1. It indicated that 4 patients had achieved a very objective tumor-response. SNTA has said that it will be continuing with the enrollment of 33 patients in each one of the 2 patient-groups that are being tested in this study. Now the trial will study a combination of ganetespib and paclitaxel, a widely-used cancer drug.

The tumor-killer

Ganetespib, the experimental drug has helped in reducing the tumor in numerous breast cancer patients and moving the study onto the next stage was something that the company was expecting to do. This drug was tested for 12-weeks in patients who were suffering from newly-diagnosed triple-negative or   HER2-positive breast cancer.

This drug blocks a protein that helps other proteins which are involved in the progression and development of the tumor in different blood and solid cancers. Synta is also testing this drug in combination with a different cancer drug that is in a late stage, lung-cancer trial. In addition, it is being tested in patients suffering from blood and colorectal cancers.

In Monday’s trading session, Synta Pharmaceuticals Corp (NASDAQ:SNTA) shares opened at $5.69 per share, reached an intraday high of $7.55 and closed at $7.15 per share. Around 21.97 million shares exchanged hand in Monday’s trading session while the average volume of shares sold over a 30-day period was 1.72 million. The company has a market cap of $494.30M.


About Ryan Mandell

Ryan Mandell is our senior staff writer covering the White House for Political Report, Ryan also coordinates with the main newsroom news items and contributing write-ups on cultural, social and political activities. Ryan holds an undergraduate degree in journalism, a Doctorate in international relations and a Master Degree in mass communications with an emphasis in print journalism. Ryan also covered the International Society of Social Defense congress in Spain in 2007 and taken part in the Global Forum on economic policies

View all post by Ryan Mandell Visit author's website

Write Your Comment